| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Peak concentration (C(max), 4.34 mg/mL). Approximately 62% of HES is excreted in urine as hydroxyethyl starch molecules within 72 hours. 5.9 L. 31.4 mL/min Metabolism / Metabolites When administered intravenously, molecules smaller than the kidney threshold (60,000-70,000 Daltons) are readily and rapidly excreted in the urine, while larger molecules are metabolized by plasma α-amylase before being excreted through the kidneys. Biological Half-Life The terminal half-life is 16.1 hours. The elimination half-life is 12 hours. |
|---|---|
| Toxicity/Toxicokinetics |
Protein Binding
No data found. |
| Additional Infomation |
See also: Starch, 2-hydroxyethyl ether, alkaline hydrolysis (note moved to).
|
| Molecular Formula |
C22H44O17
|
|---|---|
| Molecular Weight |
580.5746
|
| Exact Mass |
580.257
|
| CAS # |
9005-27-0
|
| PubChem CID |
16213095
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
39
|
| Complexity |
497
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C(COC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OCCO)OCCO)OCCO)OCCO)O.C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)O)O
|
| InChi Key |
DNZMDASEFMLYBU-RNBXVSKKSA-N
|
| InChi Code |
InChI=1S/C16H32O11.C6H12O6/c17-1-6-22-11-12-13(23-7-2-18)14(24-8-3-19)15(25-9-4-20)16(27-12)26-10-5-21;7-1-2-3(8)4(9)5(10)6(11)12-2/h12-21H,1-11H2;2-11H,1H2/t12-,13-,14+,15-,16+;2-,3-,4+,5-,6+/m11/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;2-[[(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis(2-hydroxyethoxy)oxan-2-yl]methoxy]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7224 mL | 8.6122 mL | 17.2245 mL | |
| 5 mM | 0.3445 mL | 1.7224 mL | 3.4449 mL | |
| 10 mM | 0.1722 mL | 0.8612 mL | 1.7224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT02192502
Conditions:Postoperative Kidney InjuryLink: https://clinicaltrials.gov/ct2/show/NCT03420261
Conditions:Postoperative Morbidity|Postoperative Mortality|Hemostasis ChangeLink: https://clinicaltrials.gov/ct2/show/NCT02312999
Conditions:Surgery
Title:The Effects of Intravenous Fluids on Perfusion Index and Pleth Variability Index
Status:Completed
updateDate:2017-05-16
Ctid:NCT03048162
Link: https://clinicaltrials.gov/ct2/show/NCT03048162
Conditions:PerfusionLink: https://clinicaltrials.gov/ct2/show/NCT02587078
Conditions:Severe SepsisLink: https://clinicaltrials.gov/ct2/show/NCT01689506
Conditions:BurnsLink: https://clinicaltrials.gov/ct2/show/NCT02009033
Conditions:Disorders of CoagulationLink: https://clinicaltrials.gov/ct2/show/NCT00300040
Conditions:Peripheral Vascular DiseaseLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000254-39
Condition:Anesthesia for esophageal resection because of malignancyLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017595-25
Condition:Patients undergoing colorectal surgeryPatienten mit elektiven kolorektalen EingriffenLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022816-38
Condition:Patients with elevated NT-proBNP as a sign of left ventricular dysfunction undergoing hipfracturesurgery.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014302-34
Condition:caesarean sectionLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012088-32
Condition:Akustikusneurinom mit Indikation zur operativen TherapieLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013872-29
Condition:Bowel cancers and other bowel diseases requiring surgical intervention.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009116-49
Condition:Major surgeryChirurgia maggioreLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001561-28
Condition:Adult patients (>18 years) of both gender undergoing elective colorectal surgery (hemicolectomy left/right, sigmoid colectomy, rectal resection/amputation) without concomitant resection of liver metastasisLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000729-24
Condition:Fluid/Plasma substitution during total hip replacementLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002005-45
Condition:Brain traumaLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005040-85
Condition:Intensive care patients after cardiac surgery requiring volume therapyProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
